摘要
Abstract
Objective To explore the effect of Tibivudine and tenofovir dixil on blocking treatment of pregnant women with immune tolerance of hepatitis B virus(HBV)infection.Methods A total of 104 HBV-infected pregnant women admitted to the Affiliated Hospital of Kunming University of Science and Technology in the First People's Hospital of Yunnan Province from May 2019 to October 2021 were selected as the study objects.They were randomly divided into Tibivudine group and Tenofovir dixil group by odd-even method,with 52 cases in each group.Neonatal HBV infection and block of mother-to-child transmission were recorded in the two groups after treatment.Liver function indexes,including serum albumin(ALB),total bilirubin(TBIL),alanine aminotransferase(ALT)and aspartate aminotransferase(AST),were detected before and after treatment in the two groups.The level of HBV deoxyribose(HBV-DNA)and the weight and length of newborns at birth and 12 months of age were monitored,and the occurrence of adverse reactions in the two groups of patients during treatment was recorded.Results At 7 months after birth,the positive rate of hepatitis B surface antigen(HBsAg)and hepatitis Be antigen(HBeAg)in Tenofovir dixil group was lower than that in Tibivudine group,and the blocking rate of mother-to-child transmission was higher than that in Tibivudine group,with statistical significance(P＜0.05).After treatment,the ALB level of pregnant women in both groups was higher than that before treatment,and the ALB level in tenofovir dipivoxil group was higher than that in Telbivudine group,the difference was statistically significant(P＜0.05).After treatment,the levels of TBIL,ALT and AST were decreased in both groups,and the levels in Tenofovir dixil group were more decreased than that in Tibivudine group,with statistical significance(P＜0.05).After treatment,the HBV-DNA level of pregnant women in both groups was lower than that before treatment,and the tenofovir dixil group was lower than that of Tibivudine group,with statistical significance(P＜0.05).At 12 months of age,the weight and length of the newborns in both groups increased compared with that at birth(P＜0.05),but there was no statistical significance between the two groups(P＞0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Both Tibivudine and tenofovir dixide can improve the liver function of pregnant women during the immune tolerance period of HBV infection,but Tenofovir dixide has better improvement effect and higher blocking rate.关键词
替比夫定/替诺福韦酯/乙型肝炎病毒感染免疫耐受期/孕妇/阻断Key words
Telbivudine/Tenofovir dipivoxil/HBV infection during immune tolerance period/Pregnant women/Blocking分类
医药卫生
